Pregledni rad

https://doi.org/10.20471/acc.2026.65.01.15

Janus Kinase Inhibitors – a New Effective Treatment Option for Refractory Isolated Non-infectious Ocular Inflammatory Disorders

Nina Vidic Krhlikar orcid.org/0009-0004-6146-8288 ; Eye Hospital, Ljubljana University Medical Center, Ljubljana, Slovenia
Matija Tomšič ; Eye Hospital, Ljubljana University Medical Center, Ljubljana, Slovenia;  Department of Rheumatology, Ljubljana University Medical Center, Ljubljana, Slovenia
Polona Jaki Mekjavić orcid.org/0000-0003-1949-4525 ; Eye Hospital, Ljubljana University Medical Center, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; Jožef Stefan Institute, Ljubljana, Slovenia
Pia Klobučar orcid.org/0000-0001-7717-0946 ; Eye Hospital, Ljubljana University Medical Center, Ljubljana, Slovenia
Janez Bregar ; Eye Hospital, Ljubljana University Medical Center, Ljubljana, Slovenia
Katarina Šurlan Popovič ; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia;  Clinical Institute of Radiology, Ljubljana University Medical Center, Ljubljana, Slovenia
Nataša Vidović Valentinčič orcid.org/0000-0003-4136-8242 ; Eye Hospital, Ljubljana University Medical Center, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia *

* Dopisni autor.

Sažetak

The Janus kinase (JAK) pathway regulates inflammatory responses, with dysreg-
ulation implicated in various autoimmune disorders, including non-infectious
orbital or ocular inflammation. While corticosteroids are commonly used, their
long-term use is limited by side effects. Janus kinase inhibitors (JAK-i) present an
emerging therapeutic option. This study systematically reviewed the effective-
ness and safety of JAK-i in managing isolated non-infectious ocular inflamma-
tion. A comprehensive literature review utilizing MEDLINE/PubMed, Cochrane
and Web of Science search identified studies reporting isolated non-infectious
ocular inflammation cases treated with JAK-i up to May 2025. Search terms
combined JAK-i keywords with ocular inflammation terms. Among 21 isolated
non-infectious ocular inflammation cases treated with JAK-i, tofacitinib was pre-
dominant. Most patients received JAK-i after disease-modifying antirheumatic
drug therapy, with additional corticosteroid usage. Ocular inflammation was
successfully controlled in 21 out of 21 patients, with one case of herpetic kerati-
tis necessitating additoinal systemic virostatics. JAK-i show promise as an effec-
tive option for refractory isolated non-infectious ocular inflammation. However,
further research is warranted with longer follow-up periods. Safety concerns
underline the importance of personalized risk-benefit assessments in JAK-i ther-
apy. While limitations exist, this review supports the potential of JAK-i use in
managing isolated non-infectious ocular inflammation.

Ključne riječi

Janus kinase inhibitors; Non-infectious ocular inflammation; Uveitis

Hrčak ID:

345842

URI

https://hrcak.srce.hr/345842

Datum izdavanja:

27.3.2026.

Podaci na drugim jezicima: hrvatski

Posjeta: 370 *